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lethal GVHD while maintaining GVL activity after BMT with
allogeneic naive (uncultured) thymidine kinase (TK)-expressing
transgenic T cells. However, the efﬁcacy of GCV control of
GVHD and its impact on GVL activity following BMT with ex
vivo activated, TK transduced and selected (Td) donor T cells has
not been thoroughly characterized because of the signiﬁcantly
reduced GVHD-inducing potential of cultured cells compared to
naive T cells in both preclinical models and initial clinical trials. In
these experiments, we used A20 tumor cells (B cell lymphoma of
BALB/c origin) that were modiﬁed to stably express a click beetle
red luciferase-EGFP fusion reporter gene (A20-CBRluc/egfp) and
monitored disease progression in vivo using optical biolumines-
cence imaging (BLI). To induce leukemia, BALB/c recipients were
lethally irradiated and reconstituted with C57BL/6 BM supple-
mented with or without A20-CBRluc/egfp leukemia cells. Mice
receiving leukemia cells were then left untreated or injected with
4  106 CD34-TK (chimeric fusion suicide gene) Td donor T
cells the day of BMT. Ten of ten BALB/c mice transplanted with
BM and A20-CBRluc/egfp cells exhibited tumor engraftment and
growth, with 8 mice dying from leukemia before day 35. In con-
trast, we observed no signiﬁcant tumor signal in the majority (92%)
of untreated (No GCV) mice that received CD34-TK Td T cells.
However, these animals developed GVHD with high mortality
(P  .003 compared to BM only control) and signiﬁcant weight
loss (P  .05 from day 10 onward compared to BM only control).
Although mice treated with GCV from days 4–10 after BMT were
protected from GVHD, 50% of these animals developed leukemia.
In contrast, none of the mice developed leukemia if GCV treat-
ment was delayed until day 10 after BMT. Importantly, this GVL
effect was obtained in the absence of GVHD, as evidenced by the
improved survival (88% survival at day 60 post-BMT) and weight
gain of the day 10–16 GCV treated mice compared to the un-
treated (No GCV) control. These data suggest that donor T cell
dependent GVL effects against A20 cells can be preserved while
the severity of GVHD is reduced, further demonstrating the po-
tential of the HSV-TK/GCV system to reduce acute GVHD
without impairing GVL activity.
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“MINI” METHOTREXATE AND FK506 AS GVHD PROPHYLAXIS IN PE-
DIATRIC UMBILICAL CORD BLOOD TRANSPLANTATION
Staba, S.L., Hunger, S.P., Wingard, J.R. University of Florida,
Gainesville, FL.
A majority of umbilical cord blood transplants to date utilize
steroids and cyclosporine for graft-versus-host disease (GVHD)
prophylaxis. Steroids are associated with multiple complications
including hyperglycemia, hypertension, avascular necrosis/osteo-
porosis, and signiﬁcant risk of infection. In an effort to decrease the
adverse effects of GVHD prophylaxis, we chose an alternative
combination of “mini” methotrexate (5 mg/m2  4 doses) and
FK506. Here we report our experience with this GVHD prophy-
laxis regimen. Ten children (ages 4 months to 13 years) underwent
umbilical cord blood transplant at the University of Florida be-
tween June 2004 and June 2005. All patients received a cord blood
unit that was matched at 6/6 (n  4), 5/6 (n  2), or 4/6 (n  4)
HLA loci. Children with malignant disease received either Cyclo-
phosphamide/TBI or Etoposide/TBI as the preparative regimen,
while children with non-malignant disease received Busulfan, Cy-
clophosphamide, and ATG. Umbilical cord blood cell dose ranged
from 3.4–23.7 (median 7.8)  107nucleated cells/kg. All children
received Methotrexate 5 mg/m2 on days 1, 3, 6, and 11, with
Leucovorin on days 4, 7, and 12. No doses of Methotrexate were
held. FK506 was started as a continuous infusion at day 3,
targeting levels of 10–15. The FK506 was changed to twice daily
oral dosing when tolerated. Results: 8 of the 10 children en-
grafted, with engraftment occurring at a median of 15 (range
13–38) days post transplant. Rates of acute and chronic GVHD
were low, with no grade III or IV acute GVHD seen, and no
extensive chronic GVHD occurring. Two children had grade II
acute GVHD (skin and GI). Two children developed limited
chronic GVHD of the skin while weaning FK506. GHVD resolved
completely in these patients with an increase in FK506 and were
subsequently were weaned off immunosuppression. Mucositis was
very similar to other GVHD regimens. One child became CMV
PCR positive, with CMV on bronchoscopy, however had mild
disease (never required oxygen) and recovered completely. There
were otherwise no serious infections in this patient population
beyond the time of engraftment. FK506 and “mini” Methotrexate
for GVHD prophylaxis in pediatric patients undergoing umbilical
cord blood transplant is well tolerated. Engraftment was not de-
layed and mucositis was not severe. Low rates of GHVD were seen
with minimal serious infections, making this an attractive option
for GVHD prophylaxis.
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SUCCESSFUL TREATMENT OF REFRACTORY GVHD IN AN INFANT WITH
MALIGNANT OSTEOPETROSIS WITH A HUMAN ADULT MESENCHYMAL
STEM CELL BASED DRUG
Kleiner, G.I.1, Gordon, P.1, Kuluz, J.1, Mclaughlin, G.1, Pahwa, R.2,
Ricordi, C.2, Kenyon, N.2, Monroy, R.3 1. University of Miami School of
Medicine, Miami, FL; 2. Diabetes Research Institute, Miami, FL; 3.
Osiris Therapeutics, Baltimore, MD.
It has been suggested that adult human mesenchymal stem cells
(hMSCs) have a potential to treat graft-versus-host Disease
(GVHD). At the present time, Osiris Therapeutics is in clinical
development with ProchymalTM, a cellular therapy consisting of
allogeneic bone marrow derived adult hMSCs for the treatment of
acute gastrointestinal GVHD. The present work reports a success-
ful treatment of an 8-month-old infant with grade III skin and gut
GVHD using ProchymalTM. The infant was born with hypocal-
cemia with normal phosphorus and carbonic anhydrase II, and
elevated PTH. Skeletal survey and bone marrow biopsy were
consistent with osteopetrosis. The infant received a 4/6 unrelated
cord blood transplant after standard Busulfan/Cyclophosphamide/
ATG conditioning. The ﬁrst graft failed and the patient developed
autologous reconstitution. A second transplant (4 of 6 matched
cord blood) was given at 5 months of life after Fludaribine/Cyclo-
phosphamide/ATG conditioning regimen. The patient developed
severe acute grade III skin GVHD with gastrointestinal involve-
ment in the form of bloody diarrhea that was resistant to high dose
steroids, Tacrolimus, Cellcept, and anti-CD25 antibody. A com-
passionate use protocol was developed for the treatment of the
patient with ProchymalTM. Two intravenous infusions of Prochy-
malTM were given at a dose of 8  106 cells/kg body weight each
3 days apart starting on day 100 post transplant. Both infusions
were well tolerated with no associated toxicity or reaction. By the
fourth day of treatment, there were initial signs of improvement of
the skin. By day 7, the skin improvement was dramatic and epi-
sodes of diarrhea had ceased. By day 14, the resolution of this
patient’s refractory GVHD was essentially complete. Grade IV
skin GVHD recurred approximately 1 month following initial
treatment after weaning of immune suppression. Repeat treatment
with ProchymalTM was administered starting on day 120 post
transplant and GVHD symptoms diminished within 1 week. The
patient developed 100% donor chimerism. The patient’s myeloid
engrafted improved from 8% on day 105 post transplant to 100%
by day 145. Data suggest that MSCs suppressed the adverse im-
munological response, healed damaged skin and gut tissue, and
aided in engraftment. We conclude that ProchymalTM may be
clinically useful for treatment of refractory cases of GVHD.
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SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS A POWER-
FUL MARKER OF ACUTE GRAFT-VERSUS HOST DISEASE AFTER HLA-
HAPLOIDENTICAL BONE MARROW TRANSPLANTATION
Kaida, K.1, Ikegame, K.1, Fujioka, T.1, Taniguchi, Y.1, Yoshihara, S.1,
Kawakami, M.1, Hasei, H.1, Nishida, S.1, Masuda, T.2,
Murakami, M.3, Kim, E.H.2, Tsuboi, A.1, Oji, Y.1, Oka, Y.1,
Shirakata, T.1, Kanakura, Y.1, Ogawa, H.1 1. Osaka University Grad-
uate School of Medicine, Suita, Osaka, Japan; 2. NTT WEST Osaka
Hospital, Osaka, Japan; 3. Higashiosaka General Hospital, Higash-
iosaka, Osaka, Japan.
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To examine whether serum levels of soluble interleukin-2 recep-
tor (sIL-2R) is a good marker of acute graft-versus-host disease
(aGVHD), they were measured in 37 patients receiving HLA-
haploidentical bone marrow transplantation (BMT). Grafts were
from HLA-haploidentical relatives. Conditioning regimen was
myeloablative including cyclophosphamide and toral body irradi-
ation. GVHD prophylaxis included tacrolimus (TAC)/solumedrol
(mPSL)/methotrexate (MTX) (n  11) and tacrolimus (TAC)/
solumedrol (mPSL)/methotrexate (MTX)/mycophenolate
mofetile (MMF) (n  27). Seventeen patients developed aGVHD
(Grade I, 9; Grade II, 5; Grade III, 3) after BMT. There was a
signiﬁcant correlation between occurrence of a GVHD and the
maximal serum level of sIL-2R. For 11 patients receiving GVHD
prophylaxis with TAC/mPSL/MTX, aGVHD occurred in 7 pa-
tients (63%). The mean maximal level of sIL-2R (SE) in 7
patients with a GVHD was 7086 (1066) and that in 4 patients
without aGVHD was 2770 (450). For patients with GVHD
prophylaxis with TAC/mPSL/MTX/MMF, aGVHD occurred in
10 patients (37%). The mean maximal level of sIL-2R in 10
patients with aGVHD was 3944 (655) and that in 17 patients
without aGVHD was 2566 (358). These data suggest that serum
levels of sIL-2R are useful for predicting the occurrence of
aGVHD after HLA-haploidentical BMT.
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EVALUATION FOR T CELL POPULATIONS AND CYTOKINE SHIFTS IN
NEWLY DIAGNOSED PEDIATRIC CHRONIC GRAFT-VERSUS-HOST DIS-
EASE
Schultz, K.R.1, Goldman, F.2, Aslanian, S.1, Shimizu, H.1, Krailo, M.3,
Wall, D.4, Gilman, A.L.5 1. BC Children’s Hospital/Univ. of British
Columbia, Vancouver, BC, Canada; 2. University of Iowa Medical
Center, Iowa City, IA; 3. Children’s Oncology Group, Arcadia, CA; 4.
Texas Transplant Institute, San Antonio, TX; 5. University of North
Carolina Chapel Hill, Chapel Hill, NC.
Little is known regarding the immunopathogenesis of chronic
graft-versus-host disease (cGvHD) in children. From 2001
through 2005, the Children’s Oncology Group (COG) performed
a randomized, double blinded, placebo controlled phase three
study for newly diagnosed extensive cGvHD in children and ado-
lescents, ASCT0031. Based on murine model data and limited
human studies, we hypothesized that cGvHD would be character-
ized by a Th1/Tc1 shift in T cell activation. Correlative immuno-
logic studies were performed on patients at time of enrollment to
evaluate for immune cell populations and T cell function, including
cytokine production. Twenty-seven control patients without evi-
dence of cGvHD had peripheral blood collected at 3, 6, 9, and 12
months post hematopoietic stem cell transplant (HSCT) and were
used as time matched controls. Fifty-four patients with newly
diagnosed extensive cGvHD were evaluated and divided as early
cGvHD (3–5 months post HSCT; N  20) or late-onset cGvHD
(6 months post HSCT; N 34). Signiﬁcance was determined by
either a 50% increase or decrease of the mean value compared to
control with a P value  .05. In the early-onset cGvHD patients,
the total number of CD3, CD4, and CD8T cell subsets were
all lower relative to non-cGVHD controls, although none were
signiﬁcantly different. In the late onset cGVHD patients, a non-
statistically signiﬁcant increase in CD4 and CD8 T cell pop-
ulations were noted compared to time-matched controls. Func-
tional evaluations for cytokine production after in vitro PMA/
Ionomycin stimulation (intra-cytoplasmic staining by FACS)
revealed no signiﬁcant difference in either Th1 cytokine produc-
tion (IFN) by CD4 or CD8 T cells with early-onset (P  .82,
0.81, respectively) or late onset cGVHD (P  .40, P  .33,
respectively). Evaluation for a Th2/Tc2 shift revealed that IL-4 in
either CD4 or CD8 T cells at early-onset cGvHD (P  .35,
0.11, respectively) or late-onset cGvHD (P  .54, P  .64, respec-
tively) was not different. Thus, we were unable to demonstrate
either a Th1/Tc1 or Th2/Tc2 shift associated with newly diag-
nosed cGvHD in children. These results may be different to
previous adult HSCT studies in that there may be a difference in
the biology of chronic GvHD in younger HSCT recipients or that
these studies were limited to evaluation at the time of presentation
of disease.
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BRONCHIOLITIS OBLITERANS AND BRONCHIOLITIS OBLITERANS OR-
GANIZING PNEUMONIA IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANT: AN INSTITUTIONAL EXPERIENCE
Duncan, C.N., Buonanno, M.R., Callaway, G.D., Lehmann, L.E.
Dana-Farber Cancer Institute, Boston, MA.
Bronchiolitis obliterans (BO) and bronchiolitis obliterans orga-
nizing pneumonia (BOOP) are rare, well-recognized complications
of allogeneic stem cell transplant (SCT). Both BO and BOOP are
associated with high morbidity and mortality in adult patients.
However, in the pediatric population, the incidence and morbidity
of these complications have not been well described. We report
our institutional experience of BO and BOOP in 449 pediatric
allogeneic SCT patients between January 1, 1993 and December
31, 2004. The source of stem cells in this population was as follows:
200 unrelated donors, 198 siblings, 42 parents, 5 extended family
members, and 4 half-siblings. A total of 18 patients (4%) developed
BO (n  11) or BOOP (n  7) during this time. The diagnosis of
BO was based on pulmonary function test (PFT) abnormalities
(decline in FEV1 20% of baseline or FEV1/FVC 70%) or
characteristic histologic changes on lung biopsy. BOOP was diag-
nosed by pathology only. The most common conditioning regimen
was cyclophosphamide (Cy) and total body irradiation (TBI), used
in 12 patients. Cytarabine/Cy/TBI was used in 3 cases, Busul-
fan/Cy in 2, and 1 patient received Etoposide/Cy. All but 2 patients
received bone marrow as a stem cell source; the remaining patients
received peripheral blood stem cells. Three of the patients received
stem cells from fully matched related donors; 6 of the donors were
related, but matched at less than 6 of the 6 typed HLA loci. Nine
patients received fully matched unrelated donor transplants. The
median time to diagnosis of BO or BOOP was 329 days from stem
cell infusion. Ten patients had abnormal computed tomography
scans at diagnosis. Six patients were diagnosed by PFTs alone, 9 by
pathology alone, and 3 by PFTs and pathology. All patients were
treated with immunosuppression: 16 patients received corticoste-
roids, 15 patients received calcineurin inhibitors, and 2 patients
received mycophenolate mofetil. Azithromycin was used in 3 pa-
tients for anti-inﬂammatory effects. Four patients were treated
with other medication regimens. One patient (6%) experienced
complete resolution of pulmonary disease. Three patients (17%)
achieved partial resolution. Four patients (22%) had progressive
disease. Ten patients (56%) died; 7 of pulmonary disease and 3 of
unrelated causes. BO and BOOP, while uncommon, are associated
with considerable morbidity and mortality in pediatric SCT, and
new therapeutic modalities are needed to improve the outcome of
these patients.
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CELLCEPT/CYCLOSPORINE AS PROPHYLAXIS AGAINST GRAFT- VER-
SUS-HOST DISEASE IN PEDIATRIC PATIENTS UNDERGOING ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Lakshminarayanan, S., Martin, P.L., Szabolcs, P., Driscoll, T.,
Parikh, S., Prasad, V., Kurtzberg, J. Duke University Medical Center,
Durham, NC.
Traditionally, pediatric patients are prophylaxed against acute
graft-versus-host disease (GvHD) with cyclosporine combined
with either methotrexate Mtx) or methylprednisolone (Pred). Mtx
worsens the severity of mucositis and renal insufﬁciency while pred
causes muscle wasting, hypertension and increased infections. Cell-
cept (myophenolic acid) is a better tolerated, less toxic agent with
synergistic immunosuppressive effects when combined with cyclo-
sporine or tacrolimus. We explored its use in combination with
cyclosporine in 21 pediatric patients undergoing allogeneic trans-
plantation. Patients with both malignant (n  7) and non-malig-
nant (n  14) conditions ranging in age from 2 weeks to 15 years
were transplanted after myeloablative preparative regimens with
either related bone marrow or cord blood (n 7) or unrelated cord
blood (n  14), using cellcept and cyclosporine for GVHD pro-
phylaxis. Cellcept and cyclosporine were administered intrave-
nously through the ﬁrst 40-60 days post transplant using cellcept at
a dose of 15mg/kg/dose IV q8H beginning on day -2 or -3. The
patient then transitioned to oral therapy at the same dose and
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